Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high‐dose cytarabine and mitoxantrone

Karagiannis, Panagiotis; Alsdorf, Winfried; Tallarek, Ann‐Christin; Blohm, Martin; Oelrich, Jennyfer; Waizenegger, Jonas; Wolschke, Christine; Hecher, Kurt; Singer, Dominique; Bokemeyer, Carsten; Fiedler, Walter

doi:10.1111/bjh.17220

Cited by 4 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This situation occurring in the setting of pregnancy was particularly life-threatening both for the mother and the fetus. Management of pregnant women with blood disorders is always challenging [ 14 – 16 ]. Each patient should be examined individually considering both aggressiveness of the disease and the stage of the pregnancy when a therapy is applied.…”

Section: Discussionmentioning

confidence: 99%

Delayed Severe Hemolytic Transfusion Reaction During Pregnancy in a Woman with β-Thalassemia Intermediate: Successful Outcome After Eculizumab Administration

et al. 2021

View full text Add to dashboard Cite

Patient: Female, 39-year-old Final Diagnosis: Hemolytic transfusion reaction Symptoms: Hemolysis • severe anemia Medication: — Clinical Procedure: — Specialty: Hematology Objective: Rare co-existance of disease or pathology Background: Delayed hemolytic transfusion reactions (DHTR) are life-threatening complications mostly triggered by red blood cell (RBC) transfusions in patients with hemoglobinopathy. Case Report: We present a case of DHTR and hyperhemolysis syndrome in a 39-year-old pregnant woman with a history of β-thalassemia intermediate in whom the hemoglobin (Hb) level fell to 27 g/L after transfusion of 2 units of crossmatch-compatible packed RBCs. No allo- or auto-antibody formation was detected. Administration of intravenous immunoglobulins and methylprednisolone followed by anti-CD20 rituximab was tried, but was unsuccessful. Infusions of eculizumab (900 mg twice at a 7-day interval) followed by another course of intravenous immunoglobulins (2 g/kg/day for 5 days) and combined with repeated erythropoietin injections (darbepoetin alpha 300 µg/week) finally allowed biological and clinical improvement. Blood counts remained controlled until delivery. Despite signs of intrauterine growth retardation, she gave birth by cesarean section at 31 weeks of pregnancy to a 1.15-kg infant. Conclusions: Eculizumab seems to be of benefit in DHTR associated with hyperhemolysis and should be used early in the treatment of this pathology. Despite premature birth, our case report showed an acceptable outcome for the infant when eculizumab treatment was used during pregnancy.

show abstract

Section: Discussionmentioning

confidence: 99%